In our study, Lactobacillus oris treatment increased the expressions of both FXR and SREBP-2 in the liver of mice, suggesting that it might improve NAFLD through the FXR and SREBP pathways. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.